Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05376800 |
| Title | A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase Ia) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Boehringer Ingelheim |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
CKB BOOST